Tezosentan
Appearance
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H27N9O6S |
Molar mass | 605.624 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Tezosentan is a non-selective ETA and ETB receptor antagonist.[1] It acts as a vasodilator and was designed as a therapy for patients with acute heart failure. Recent studies have shown however, that tezosentan does not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.[2]
References
- ^ Urbanowicz, W; Sogni, P; Moreau, R; Tazi, K A; Barriere, E; Poirel, O; Martin, A; Guimont, M C; Cazals-Hatem, D; Lebrec, D (2004). "Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats". Gut. 53 (12). BMJ Publishing Group Ltd & British Society of Gastroenterology: 1844–1849. doi:10.1136/gut.2003.036517. PMC 1774327. PMID 15542526.
- ^ "Tezosentan does not appear to improve symptoms for patients with acute heart failure". Medical Studies/Trials. news-medical.net. 7 Nov 2007. Retrieved 2007-11-24.